FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2897618102> ?p ?o ?g. }

• W2897618102 endingPage "e000428" @default.
• W2897618102 startingPage "e000428" @default.
• W2897618102 abstract "Adjuvant Chemotherapy Trial of TS-1 for Colon Cancer (ACTS-CC), a randomised phase III trial, demonstrated that adjuvant therapy with S-1 for stage III colon cancer was non-inferior in 3-year disease-free survival (DFS) to that of tegafur-uracil plus leucovorin (UFT/LV). We updated DFS and overall survival (OS) and performed T x N subset analysis.A total of 1518 patients with curatively resected stage III colon cancer were randomly assigned to receive S-1 (80-120 mg/day on days 1-28 every 42 days, four courses) or UFT/LV (UFT: 300-600 mg/day and LV: 75 mg/day on days 1-28 every 35 days, five courses).The 5-year DFS rates of the S-1 and UFT/LV group were 70.2 % and 66.9 %, respectively (HR 0.88; 95% CI 0.74 to 1.06; p=0.177), and non-inferiority of DFS was reconfirmed with a median of 63.5-month follow-up. The similarity of OS was also confirmed (HR 0.92; 95% CI 0.72 to 1.17; p=0.488); 5-year OS rates of the S-1 and UFT/LV group were 86.0 % and 84.4 %, respectively. No significant interactions were identified between the major baseline characteristics and DFS of the S-1 and UFT/LV groups, except for histological type; S-1 was more favourable in patients with poorly differentiated adenocarcinoma. Patient outcomes were well separated by TNM-substages (IIIA/IIIB/IIIC). With the patients divided into 20 subsets by T and N factors, the DFS and OS rates of T3 and N1 subset, which accounted for 62 % of stage IIIB patients and 44 % of all studied subjects, were significantly better than those of the other subsets in stage IIIB and similar to those of stage IIIA.Adjuvant therapy of S-1 for stage III colon cancer was reconfirmed to be non-inferior in DFS to those of UFT/LV after long follow-up. No difference in OS was also demonstrated. T3N1 patients might be considered separately from other patients included in stage IIIB because of its favourable outcome.NCT00660894." @default.
• W2897618102 created "2018-10-26" @default.
• W2897618102 creator A5001002762 @default.
• W2897618102 creator A5010999012 @default.
• W2897618102 creator A5014061571 @default.
• W2897618102 creator A5016882239 @default.
• W2897618102 creator A5018138745 @default.
• W2897618102 creator A5021229169 @default.
• W2897618102 creator A5026639791 @default.
• W2897618102 creator A5027257802 @default.
• W2897618102 creator A5037263900 @default.
• W2897618102 creator A5046397472 @default.
• W2897618102 creator A5048058848 @default.
• W2897618102 creator A5049839257 @default.
• W2897618102 creator A5059829141 @default.
• W2897618102 creator A5059988632 @default.
• W2897618102 creator A5065433705 @default.
• W2897618102 creator A5070355356 @default.
• W2897618102 creator A5084276407 @default.
• W2897618102 creator A5085570487 @default.
• W2897618102 creator A5087398756 @default.
• W2897618102 date "2018-01-01" @default.
• W2897618102 modified "2023-09-30" @default.
• W2897618102 title "Updated 5-year survival and exploratory T x N subset analyses of ACTS-CC trial: a randomised controlled trial of S-1 versus tegafur-uracil/leucovorin as adjuvant chemotherapy for stage III colon cancer" @default.
• W2897618102 cites W1934256528 @default.
• W2897618102 cites W2012309973 @default.
• W2897618102 cites W2082439374 @default.
• W2897618102 cites W2100530362 @default.
• W2897618102 cites W2118415193 @default.
• W2897618102 cites W2119938514 @default.
• W2897618102 cites W2125016589 @default.
• W2897618102 cites W2138985803 @default.
• W2897618102 cites W2140535403 @default.
• W2897618102 cites W2141768150 @default.
• W2897618102 cites W2144495943 @default.
• W2897618102 cites W2153535407 @default.
• W2897618102 cites W2168600267 @default.
• W2897618102 cites W2412717755 @default.
• W2897618102 cites W2765911847 @default.
• W2897618102 cites W2795004907 @default.
• W2897618102 doi "https://doi.org/10.1136/esmoopen-2018-000428" @default.
• W2897618102 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6212676" @default.
• W2897618102 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30425843" @default.
• W2897618102 hasPublicationYear "2018" @default.
• W2897618102 type Work @default.
• W2897618102 sameAs 2897618102 @default.
• W2897618102 citedByCount "9" @default.
• W2897618102 countsByYear W28976181022020 @default.
• W2897618102 countsByYear W28976181022021 @default.
• W2897618102 countsByYear W28976181022022 @default.
• W2897618102 countsByYear W28976181022023 @default.
• W2897618102 crossrefType "journal-article" @default.
• W2897618102 hasAuthorship W2897618102A5001002762 @default.
• W2897618102 hasAuthorship W2897618102A5010999012 @default.
• W2897618102 hasAuthorship W2897618102A5014061571 @default.
• W2897618102 hasAuthorship W2897618102A5016882239 @default.
• W2897618102 hasAuthorship W2897618102A5018138745 @default.
• W2897618102 hasAuthorship W2897618102A5021229169 @default.
• W2897618102 hasAuthorship W2897618102A5026639791 @default.
• W2897618102 hasAuthorship W2897618102A5027257802 @default.
• W2897618102 hasAuthorship W2897618102A5037263900 @default.
• W2897618102 hasAuthorship W2897618102A5046397472 @default.
• W2897618102 hasAuthorship W2897618102A5048058848 @default.
• W2897618102 hasAuthorship W2897618102A5049839257 @default.
• W2897618102 hasAuthorship W2897618102A5059829141 @default.
• W2897618102 hasAuthorship W2897618102A5059988632 @default.
• W2897618102 hasAuthorship W2897618102A5065433705 @default.
• W2897618102 hasAuthorship W2897618102A5070355356 @default.
• W2897618102 hasAuthorship W2897618102A5084276407 @default.
• W2897618102 hasAuthorship W2897618102A5085570487 @default.
• W2897618102 hasAuthorship W2897618102A5087398756 @default.
• W2897618102 hasBestOaLocation W28976181021 @default.
• W2897618102 hasConcept C121608353 @default.
• W2897618102 hasConcept C126322002 @default.
• W2897618102 hasConcept C141071460 @default.
• W2897618102 hasConcept C146357865 @default.
• W2897618102 hasConcept C151730666 @default.
• W2897618102 hasConcept C168563851 @default.
• W2897618102 hasConcept C2776694085 @default.
• W2897618102 hasConcept C2777299880 @default.
• W2897618102 hasConcept C2777863537 @default.
• W2897618102 hasConcept C3018227240 @default.
• W2897618102 hasConcept C526805850 @default.
• W2897618102 hasConcept C530470458 @default.
• W2897618102 hasConcept C71924100 @default.
• W2897618102 hasConcept C86803240 @default.
• W2897618102 hasConcept C90924648 @default.
• W2897618102 hasConceptScore W2897618102C121608353 @default.
• W2897618102 hasConceptScore W2897618102C126322002 @default.
• W2897618102 hasConceptScore W2897618102C141071460 @default.
• W2897618102 hasConceptScore W2897618102C146357865 @default.
• W2897618102 hasConceptScore W2897618102C151730666 @default.
• W2897618102 hasConceptScore W2897618102C168563851 @default.
• W2897618102 hasConceptScore W2897618102C2776694085 @default.
• W2897618102 hasConceptScore W2897618102C2777299880 @default.
• W2897618102 hasConceptScore W2897618102C2777863537 @default.
• W2897618102 hasConceptScore W2897618102C3018227240 @default.
• W2897618102 hasConceptScore W2897618102C526805850 @default.

• next